Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer

Journal of B.U.ON.

Volumn 16, Issue 2, 2011, Pages 215-218

  Saloustros, E ^a   Kalbakis, K ^a   Vardakis, N ^a   Kalykaki, A ^a   Milaki, G ^a   Rovithi, M ^a   Agelaki, S ^a   Saridaki, Z ^a   Georgoulias, V ^a   Mavroudis, Dimitris ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Bevacizumab; Breast cancer; Metronomic; Salvage; Vinorelbine

Indexed keywords

BEVACIZUMAB; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HUMAN; HYPERTENSION; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; SALVAGE THERAPY; TREATMENT RESPONSE; VASCULAR DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 79960284087     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205. (Pubitemid 26264869)
2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-984. (Pubitemid 28455101)
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
4. Cobleigh M, Langmuir VK, Sledge GW et al. A phase II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-124. (Pubitemid 37433402)
5. Miller KD, Chap L, Frankie A et al. Randomized Phase III Trial of Capecitabine Compared with Bevacizumab plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. J Clin Oncol 2005; 23: 792-299.
6. Briasoulis E, Pappas P, Puozzo C et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 2009; 15: 6454-6461.
7. Miller KD, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
8. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
9. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 1999; 17: 2971-2994. (Pubitemid 29415258)
10. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women with Breast Cancer. J Clin Oncol 2003; 21: 4042-4057.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Simon R. Optimal two stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Burstein HJ, Chen YH, Parker LM et al. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy. Clin Cancer Res 2008; 14: 7871-7877.
15. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 21: 257-272.